1:52 am Agios Pharma reports initial Phase 1 data demonstrating clinical activity of AG-221, first-in-class inhibitor of IDH2 mutations, in patients with advanced blood cancers
View todays social media effects on AGIO
View the latest stocks trending across Twitter. Click to view dashboard
See who Agios is hiring next, click here to view
